Clinical impact following the establishment of a specialized brain metastases tumor board.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-06-23 DOI:10.1007/s12094-025-03949-3

Izaskun Valduvieco, Gabriela Antelo, Alberto Di Somma, Mireia Alvarez, Sebastian Capurro, MLourdes Olondo, Ana Arance, Laura Ferrer-Mileo, Iban Aldecoa, Carme Ares, Tanny Barreto, Alejandra Mosteiro, Josep Gonzalez, Joaquim Enseñat, Meritxell Mollà

{"title":"Clinical impact following the establishment of a specialized brain metastases tumor board.","authors":"Izaskun Valduvieco, Gabriela Antelo, Alberto Di Somma, Mireia Alvarez, Sebastian Capurro, MLourdes Olondo, Ana Arance, Laura Ferrer-Mileo, Iban Aldecoa, Carme Ares, Tanny Barreto, Alejandra Mosteiro, Josep Gonzalez, Joaquim Enseñat, Meritxell Mollà","doi":"10.1007/s12094-025-03949-3","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the impact of brain metastasis tumor board (BMTB) on treatment patterns and survival.Methods: 365 patients with brain metastases (BM) were analyzed at the Hospital Clínic de Barcelona from October 2019 to October 2022. This included those treated in the department of neurosurgery and radiation oncology during the first 18 months following its establishment. Demographic, clinicopathological, and treatment data were recorded and compared between the groups with and without BTBM.Results: Of 365, 95 were in the BMTB group and 270 in the non-BMTB group. Patients discussed at the BMTB had higher rates of surgery (53.7% vs. 14.7%, p < 0.001) and stereotactic radiosurgery (63.1% vs. 21.6%, p < 0.001). The time between surgical treatment and adjuvant radiotherapy was shorter in the BMTB group (37 days, 95% CI 4 vs. 48 days, 95% CI 18, p = 0.018). No differences were observed in local progression (26.0% vs. 20.8%, p = 0.9) but there were differences in cerebral progression (43.2% vs. 27.4%, p = 0.004). Rescue treatment was more common in the BMTB group (26.3% vs 10.0%, p < 0.001). Median survival after BM was significantly longer in the BMTB group (28.2 ± 2.7 vs. 12.7 ± 1.04 months, p < 0.001).Conclusion: Multidisciplinary discussions for patients with BM are crucial as they improve overall survival through integrated therapies. Additional trials are needed to optimize treatment integration in this complication.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03949-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the impact of brain metastasis tumor board (BMTB) on treatment patterns and survival.

Methods: 365 patients with brain metastases (BM) were analyzed at the Hospital Clínic de Barcelona from October 2019 to October 2022. This included those treated in the department of neurosurgery and radiation oncology during the first 18 months following its establishment. Demographic, clinicopathological, and treatment data were recorded and compared between the groups with and without BTBM.

Results: Of 365, 95 were in the BMTB group and 270 in the non-BMTB group. Patients discussed at the BMTB had higher rates of surgery (53.7% vs. 14.7%, p < 0.001) and stereotactic radiosurgery (63.1% vs. 21.6%, p < 0.001). The time between surgical treatment and adjuvant radiotherapy was shorter in the BMTB group (37 days, 95% CI 4 vs. 48 days, 95% CI 18, p = 0.018). No differences were observed in local progression (26.0% vs. 20.8%, p = 0.9) but there were differences in cerebral progression (43.2% vs. 27.4%, p = 0.004). Rescue treatment was more common in the BMTB group (26.3% vs 10.0%, p < 0.001). Median survival after BM was significantly longer in the BMTB group (28.2 ± 2.7 vs. 12.7 ± 1.04 months, p < 0.001).

Conclusion: Multidisciplinary discussions for patients with BM are crucial as they improve overall survival through integrated therapies. Additional trials are needed to optimize treatment integration in this complication.

查看原文本刊更多论文

建立专门的脑转移瘤委员会后的临床影响。

目的：探讨脑转移瘤板（BMTB）对治疗方式和生存率的影响。方法：对2019年10月至2022年10月Clínic de Barcelona医院365例脑转移（BM）患者进行分析。这包括在成立后的前18个月在神经外科和放射肿瘤科接受治疗的患者。记录人口统计学、临床病理学和治疗数据，并比较有和无BTBM组之间的差异。结果：365例患者中，BMTB组95例，非BMTB组270例。在BMTB上讨论的患者有更高的手术率（53.7% vs. 14.7%）。结论：多学科讨论对BM患者至关重要，因为他们通过综合治疗提高了总体生存率。需要进一步的试验来优化该并发症的综合治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.